GJMic.070204

Research Article

Diagnosis and Treatment of Central Nervous System Aspergillosis: A Report of 3 Cases and Literature Review

 

Fangjie Liu1,#, Yuling Huang1,#, Haimei Deng1, Bo Lu1, Xiaojun Xu1, Xiaobo Wang1,*

1Department of Hematology, the Seventh Hospital of Sun Yat-Sen University, Shenzhen 518107, China.

#, Authors contributed equally.
*, Correspondence
Professor Xiaobo Wang, MD, Department of Hematology, the Seventh Hospital of Sun Yat-Sen University, Shenzhen 518107, China. E-mail: wangxiaobo@sysush.com.
Received: July 1, 2026. Accepted: July 17, 2026. Published online: November 16, 2026.
Cite this paper: Fangjie Liu, Yuling Huang, Haimei Deng, Bo Lu, Xiaojun Xu, Xiaobo Wang. Prospective interception at the low fungal burden stage: a comparative study of diagnostic-driven versus empiric antifungal strategies in febrile patients with hematological malignancies. Global Journal of Microbiology, 2026;7(2):38-51. http://naturescholars.com/gjmic.070204. https://doi.org/10.46633/gjmic.070204.
Copyright © 2026 by Scholars Publishing, LLC.

Abstract

Background: Central nervous system (CNS) aspergillosis is a rare but devastating invasive fungal infection, with mortality exceeding 80% even with antifungal therapy. Patients with hematologic malignancies and those undergoing allogeneic hematopoietic stem cell transplantation (allo‑HSCT) are at particularly high risk, especially when receiving prolonged glucocorticoids or T‑cell immunosuppressants. The diagnosis is notoriously difficult because clinical manifestations are nonspecific, conventional cerebrospinal fluid (CSF) cultures have very low sensitivity, and brain biopsy is often contraindicated due to thrombocytopenia. Next-generation sequencing (NGS) of CSF has emerged as a promising unbiased diagnostic tool, but its clinical utility in this setting requires further illustration. Methods: We retrospectively collected three cases of CNS aspergillosis in patients with underlying hematologic diseases treated at our institution. All patients had received prolonged immunosuppressive therapy, including glucocorticoids for >3 weeks; two also received T-cell inhibitors such as ruxolitinib or basiliximab. CSF samples were obtained by lumbar puncture and subjected to metagenomic NGS for pathogen identification. Antifungal regimens, imaging findings, and clinical outcomes were reviewed. Results: The three patients (one with pancytopenia complicated by hemophagocytic syndrome, two post-allo-HSCT with severe graft-versus-host disease) all presented with fever and neurological symptoms (headache, aphasia, confusion, or seizure). Two had documented pulmonary aspergillosis prior to CNS involvement. CSF NGS detected Aspergillus flavus in two cases and A. fumigatus in one, whereas conventional cultures and serum biomarkers remained negative. Brain MRI revealed characteristic lesions including choroid plexus enhancement, multifocal infarcts, and hemorrhagic changes. Two patients developed CNS disease while already on liposomal amphotericin B for pulmonary infection (one also had isavuconazole added), indicating breakthrough infections. Despite antifungal therapy, all patients showed rapid neurological deterioration; one died of cerebral hemorrhage, and the other two were discharged against medical advice with irreversible neurological damage and likely fatal outcomes. Conclusions: CSF NGS is a highly sensitive and specific diagnostic tool for CNS aspergillosis in hematologic patients, offering a major advantage over conventional methods, particularly when prior antifungal therapy has been given. The occurrence of breakthrough infections despite combination therapy with agents that penetrate the blood-brain barrier strongly suggests the presence of azole resistance. Our cases underscore the urgent need for early CSF NGS, routine antifungal susceptibility testing, and therapeutic drug monitoring to improve the currently grim prognosis of this lethal complication.

Keywords

Central nervous system (CNS); aspergillosis; hematologic diseases; next‑generation sequencing (NGS); breakthrough.